Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/12/2021 | $7.00 | Buy | ThinkEquity |
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
Peer-Reviewed Study Demonstrates Feasibility and Statistically Significant Improvements in Subjective Clinical Outcomes in Dogs with Stifle Osteoarthritis and Suspected Cranial Cruciate Disease Minneapolis, MN, July 14, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)), in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc., Cosmeta Corp and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, today announced the publication of a peer-reviewed clinical study evaluating Spryng® with OsteoCushion® Technology in the peer-reviewed journal Veterinary Record. The publication repre
MINNEAPOLIS, MN, US, June 29, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV) (OTCID: PETVW), in cooperation with its wholly-owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, reported operational results for the fourth quarter of its fiscal year ended March 31, 2026, and financial results for the full fiscal year. PetVivo will hold a conference call today at 5:00 p.m. Eastern time to discuss the results and provide a business update, followed by a question-and-answer session (see dial-in information below). Fiscal Q4 Operational Highlights
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing. REGISTER AND VIEW PRESENTATIONS HERE Select companies are accepting 1x1 management meeting requests through June 19th. Please Schedule 1x1 Meetings here. The presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Presenting Companies CompanyTicker(s)MetaVia Inc.(NASDAQ:MTVA)Nasus Pharma Ltd.(NYSE:NSRX)CytoSorbents Corporation(NASD
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
10-K - PetVivo Holdings, Inc. (0001512922) (Filer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
MINNEAPOLIS, MN, US, Oct. 28, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID PETVW)), in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc., both emerging biomedical device companies focused on the commercialization of innovative medical therapeutics for companion animals and animal athletes is pleased to announce that Josh Ruben has joined the Company's Board of Directors. "We are honored to welcome Josh Ruben to our Board of Directors," said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "Josh brings a wealth of experience in healthcare finance, capital markets, and corporate strategy, with a proven track record of executing multi-b
Minneapolis, MN, June 06, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, OTC:PETVW), an emerging biomedical device company focused on animal health, today announced a strategic collaboration with Commonwealth, the syndicated ownership group behind 2023 Kentucky Derby winner Mage, and 2022 Dubai World Cup Champion Country Grammer. The partnership centers on the clinical use and promotion of SPRYNG® with OsteoCushion® Technology, PetVivo's cutting-edge intra-articular device designed to support joint health and durability, and Precise PRP™, a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians in elite equine athletes. As part of t
PetVivo Board Appoints Eldred as Executive Director to Lead Company Product Commercialization and Operations MINNEAPOLIS, MN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW)), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Mike Eldred as the Company's Commercialization and Operations Advisor. His appointment as an Executive Director by the Company's Board of Directors draws upon Mr. Eldred's 30 years of executive experience in animal health and the veterinary industry to ramp up its product development and sales efforts. For the past 20 years, Mr. Eldred served as President of North American Operations for Dech
ThinkEquity initiated coverage of PetVivo Holdings with a rating of Buy and set a new price target of $7.00
MINNEAPOLIS, MN, US, June 29, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV) (OTCID: PETVW), in cooperation with its wholly-owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, reported operational results for the fourth quarter of its fiscal year ended March 31, 2026, and financial results for the full fiscal year. PetVivo will hold a conference call today at 5:00 p.m. Eastern time to discuss the results and provide a business update, followed by a question-and-answer session (see dial-in information below). Fiscal Q4 Operational Highlights
MINNEAPOLIS, MN, US, June 25, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV) (OTCID: PETVW), in cooperation with its wholly-owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, will report financial results for the year ending March 31, 2026, on Monday, June 29, 2026 after market close. The company will host a conference call to discuss these results at 5:00 p.m. CT (6:00 p.m. ET) on the same day. Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo’s Investor
MINNEAPOLIS, MN, US, Feb. 17, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTC ID: PETVW)), and its wholly owned subsidiaries PetVivo Animal Health and PetVivo AI, a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, reported financial and operational results for the third quarter and first nine months of its fiscal year 2026 ended December 31, 2025. The company will hold a conference call today at 5:00 p.m. Eastern time to discuss the results and provide a business update, followed by a question-and-answer session (see dial-in information below). Fiscal Q3 Operational Highlights Signed an exclusive 10-ye
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)